SMO and skin basal cell carcinoma: Vismodegib, the first-in-class SMO inhibitor, was approved by the FDA (January 2012) and EMA (July 2013) for the treatment of laBCC not eligible for radical surgery/RT, as well as for mBCC.13,14 In phase II, ERIVANCE BCC trial,17 daily 150 mg achieved complete response (CR) rates of 32% (20/63) in laBCC and 0% (0/33) in mBCC, respectively.18 CTCAE grades 3-4 adverse events (AEs) occurred within a range of 23%-55%, leading to permanent drug discontinuation in 21% of cases.